Alzheimer's Disease Clinical Trial
Official title:
Assessing the Effects of a Personalized Music Therapy With Headphones on Agitation in Patients With Dementia
Verified date | September 2019 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Symptoms of agitation include abuse or aggressive behaviour toward self or others,
appropriate behaviour performed with inappropriate frequency, or behaviours that are
inappropriate according to social standards. In the later stages of dementia agitation can
contribute significantly to patient distress and caregiver stress, and has been associated
with poor quality of life. Previous research studies have shown some evidence that
personalized music played in daily care situations reduces agitation. The purpose of this
study is to evaluate the effects of personalized music therapy via headphones on agitation
during hygiene care (grooming).
This study will involve 60 in-patients of the Geriatric Psychiatry ward of Toronto
Rehabilitation Institute. The study would take place over the span of 2 weeks and would
involve listening to personalized and either non-personalized or no music during daily
hygiene care (grooming). Enrolment is completely voluntary and all personal data obtained
will remain confidential.
Status | Enrolling by invitation |
Enrollment | 60 |
Est. completion date | June 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of dementia with possible or probable cause of Alzheimer's disease, Vascular disease, mixed dementia; - moderate stage of dementia, a score of <20 on MMSE; - Age 60 to 90 inclusive; - Preserved hearing (hearing aids are permissible); - Pittsburgh agitation scale score of = 3 on at least on 3 occasions over a period of 5 days. Exclusion Criteria: - auditory deficits requiring correction beyond hearing aids. - no substitute decision maker available to indicate music preference and patient unable to answer for themselves. - recent acute event eg. MI, fractures, or major infection (not UTI) - patients receiving standing orders of medication for personal care |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in agitation | Changes in agitation as measured by the Pittsburgh agitation questionnaire and "as needed" psychotropic medications for agitation required during hygiene care will be quantitatively assessed. Statistical analyses will be performed to compare levels of agitation and use of "as needed" psychotropic medications for agitation with personalized music therapy with headphones and non-personalized music intervention or usual care. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT01920672 -
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
|
N/A |